Knight Therapeutics Inc. (TSE:GUD) Director Purchases C$99,998.70 in Stock

Knight Therapeutics Inc. (TSE:GUDGet Rating) Director Samira Sakhia purchased 19,455 shares of Knight Therapeutics stock in a transaction dated Monday, June 20th. The shares were purchased at an average price of C$5.14 per share, for a total transaction of C$99,998.70. Following the completion of the acquisition, the director now owns 158,954 shares of the company’s stock, valued at approximately C$817,023.56.

Samira Sakhia also recently made the following trade(s):

  • On Wednesday, May 18th, Samira Sakhia purchased 19,305 shares of Knight Therapeutics stock. The shares were purchased at an average price of C$5.18 per share, for a total transaction of C$99,999.90.

Shares of GUD opened at C$5.11 on Thursday. Knight Therapeutics Inc. has a 52-week low of C$5.01 and a 52-week high of C$5.74. The company has a debt-to-equity ratio of 5.64, a quick ratio of 2.05 and a current ratio of 2.73. The business’s 50 day moving average price is C$5.30 and its two-hundred day moving average price is C$5.34. The firm has a market cap of C$589.13 million and a PE ratio of -92.91.

Knight Therapeutics (TSE:GUDGet Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported C($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of C($0.04) by C$0.02. The business had revenue of C$63.81 million during the quarter, compared to analyst estimates of C$52.80 million. Research analysts predict that Knight Therapeutics Inc. will post -0.02 EPS for the current fiscal year.

Several research firms have recently weighed in on GUD. National Bankshares reduced their price target on Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating on the stock in a report on Friday, March 25th. Raymond James set a C$7.50 price objective on Knight Therapeutics and gave the stock an “outperform” rating in a research note on Friday, April 1st. Canaccord Genuity Group cut their price objective on Knight Therapeutics from C$8.00 to C$7.00 in a research note on Friday, March 25th. National Bank Financial cut their price objective on Knight Therapeutics from C$8.00 to C$7.50 and set an “outperform” rating on the stock in a research note on Friday, March 25th. Finally, Bloom Burton reaffirmed a “buy” rating and issued a C$6.70 price objective on shares of Knight Therapeutics in a research note on Monday, March 28th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Knight Therapeutics has an average rating of “Moderate Buy” and an average target price of C$7.00.

Knight Therapeutics Company Profile (Get Rating)

Knight Therapeutics Inc, a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma.

See Also

Insider Buying and Selling by Quarter for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.